1990 - 92 |
American College of Physicians, Associate |
| 1992 - 98 |
American College of Physicians, Member |
1992 |
American Association of the Advancement of Science, Member |
1993 - 96 |
American Association for Cancer Research, Associate |
1995 - |
American Society of Clinical Oncology, Member |
1996 - |
American Association for Cancer Research, Member |
1997 - |
American Urological Association, Affiliate Member |
1997 - |
International Society of Differentiation, Member |
| 1998 - |
American College of Physicians, Fellow |
1999 - |
National Kidney Cancer Foundation, Member |
1999 |
National Cancer Center Network, Task Force on Supportive Care, Member |
2001 |
National Cancer Center Network, Subcommittee on Renal Cell/Testicular Cancer, Member |
1999 - |
National Cancer Center Network, Subcommittee on Palliative Care, Member |
1999 |
1999 Member, Advisory Committee for Johns Hopkins Early Diagnosis Research Network – EDRN Clinical Tumor Marker Testing Center (Chair – Alan Partin, M.D., Ph.D.) |
2000 |
2000 Member, External Advisory Panel to Genitourinary Oncology Research Program, University of Chicago Cancer Center |
2003 |
Data Safety Monitoring Board, Merck , Inc (Vioxx in Prostate Cancer) |
2005 |
2005 Panel Member, Molecular Targets and Drug Development Working Group, National Cancer Institute Advisory Committee to SPORE Program |
2004-2007 |
Data Safety Monitoring Board, GPC Biotech (Satraplatin in Prostate Cancer |
2007-2010 |
2007-2010 Data Safety Monitoring Committee, Sanofi-Aventis (VEGF-TRAP in Prostate Cancer) |
2007-2011 |
2007-2010 Data Safety Monitoring Committee, Sanofi-Aventis (VEGF-TRAP in Prostate Cancer) |
2008 – 2010 |
Data Safety Monitoring Committee, Internal Invesigator Initiated Study (C-Novyi in Solid Tumors- L. Diaz, PI) |
